Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Net Cash Flow of -$19.4 million for Q1 2026, down 335.65% on a QoQ basis from -$4.5 million in Q4 2025, and up 3.43% year-over-year from -$18.7 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$19.4 million for Q1 2026.
- Quarterly Net Cash Flow rose 3.43% year-over-year to -$19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (up 15.42% YoY) and the FY2025 annual result came in at -$61.1 million, down 11.17% from the prior year.
- Net Cash Flow was -$19.4 million for Q1 2026 at Arcturus Therapeutics Holdings, down from -$4.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $154.2 million in Q4 2022 and bottomed at -$63.9 million in Q1 2023.
- A 5-year average of -$9.4 million and a median of -$20.1 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 455.47% — and 2025, when it plunged 2867.33%.
- Arcturus Therapeutics Holdings' Net Cash Flow stood at $154.2 million in 2022, then plunged by 113.07% to -$20.2 million in 2023, then jumped by 99.26% to -$150000.0 in 2024, then plunged by 2867.33% to -$4.5 million in 2025, then tumbled by 335.65% to -$19.4 million in 2026.
- Business Quant data shows ARCT's Net Cash Flow at -$19.4 million in Q1 2026, -$4.5 million in Q4 2025, and -$16.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -19.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.39 Mn |
| Mar 31, 2026 | -19.39 Mn |
| Dec 31, 2025 | -4.45 Mn |
| Dec 31, 2025 | -4.45 Mn |
| Sep 30, 2025 | -16.11 Mn |
| Sep 30, 2025 | -16.11 Mn |
| Jun 30, 2025 | -20.48 Mn |
| Jun 30, 2025 | -20.48 Mn |
| Mar 31, 2025 | -20.08 Mn |
| Mar 31, 2025 | -20.08 Mn |
| Dec 31, 2024 | -150,000.00 |
| Dec 31, 2024 | -150,000.00 |
| Sep 30, 2024 | -23.15 Mn |
| Sep 30, 2024 | -23.15 Mn |
| Jun 30, 2024 | -28.07 Mn |
| Jun 30, 2024 | -28.07 Mn |
| Mar 31, 2024 | -3.61 Mn |
| Mar 31, 2024 | -3.61 Mn |
| Dec 31, 2023 | -20.16 Mn |
| Dec 31, 2023 | -20.16 Mn |